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A crucial role for DOK1 in PDGF-BB-stimulated glioma cell
invasion through p130Cas and Rap1 signalling
Angela Barrett, Ian M. Evans, Antonina Frolov, Gary Britton, Caroline Pellet-Many, Maiko Yamaji, Vedanta Mehta,
Rina Bandopadhyay, Ningning Li, Sebastian Brandner, Ian C. Zachary and Paul Frankel
There was an error published in J. Cell Sci. 127, 2647-2658.
In the Abstract and Introduction, TERF2IP was incorrectly given as an alternative name for Rap1. This should have referred to the small
GTPase Rap1 (which has two isoforms, Rap1a and Rap1b).
We apologise to the readers for any confusion that this error might have caused.
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A crucial role for DOK1 in PDGF-BB-stimulated glioma cell
invasion through p130Cas and Rap1 signalling
Angela Barrett1,*, Ian M. Evans1,*, Antonina Frolov1, Gary Britton1, Caroline Pellet-Many1, Maiko Yamaji1,
Vedanta Mehta1, Rina Bandopadhyay2, Ningning Li3, Sebastian Brandner3, Ian C. Zachary1 and Paul Frankel1,`
ABSTRACT
DOK1 regulates platelet-derived growth factor (PDGF)-BB-stimulated
glioma cell motility. Mechanisms regulating tumour cell motility are
essential for invasion and metastasis. We report here that PDGF-BB-
mediated glioma cell invasion and migration are dependent on the
adaptor protein downstream of kinase 1 (DOK1). DOK1 is expressed
in several glioma cell lines and in tumour biopsies from high-grade
gliomas. DOK1 becomes tyrosine phosphorylated upon PDGF-BB
stimulation of human glioma cells. Knockdown of DOK1 or expression
of a DOK1mutant (DOK1FF) containing Phe in place of Tyr at residues
362 and 398, resulted in inhibition of both the PDGF-BB-induced
tyrosine phosphorylation of p130Cas (also known as BCAR1) and the
activation of Rap1 (also known as TERF2IP). DOK1 colocalises with
tyrosine phosphorylated p130Cas at the cell membrane of PDGF-BB-
treated cells. Expression of a non-tyrosine-phosphorylatable substrate
domain mutant of p130Cas (p130Cas15F) inhibited PDGF-BB-
mediated Rap1 activation. Knockdown of DOK1 and Rap1 inhibited
PDGF-BB-induced chemotactic cell migration, and knockdown of
DOK1 and Rap1 and expression of DOK1FF inhibited PDGF-
mediated three-dimensional (3D) spheroid invasion. These data
show a crucial role for DOK1 in the regulation of PDGF-BB-
mediated tumour cell motility through a p130Cas–Rap1 signalling
pathway.
KEY WORDS: Cell motility, PDGF signalling, DOK1, p130Cas,
GTPase
INTRODUCTION
The acquisition of increased cell motility gives tumour cells the
capacity to invade their surrounding tissue, and is described as
one of the ‘hallmarks of cancer’ (Hanahan and Weinberg, 2011).
However, specific chemotactic signalling pathways involved in
the regulation of tumour cell motility and three-dimensional (3D)
invasion are not well understood. Platelet derived growth factor
(PDGF)-BB is an important ligand regulating cell motility in both
non-transformed and cancer cells (Jones and Cross, 2004).
The expression of PDGF and PDGF receptor is deregulated in a
variety of cancers, including glioblastoma, melanoma, breast
carcinoma, prostate carcinoma and various forms of leukaemia
(Heldin and Westermark, 1999).
Glioblastoma is a highly invasive primary malignant brain
tumour. Glioblastoma cells migrate and proliferate preferentially
along fibre tracts and blood vessels, resulting in a diffuse
infiltration of brain tissue. It has been proposed that glioma cells
are attracted to blood vessels by growth factors produced by
endothelial cells, such as PDGF-BB (Farin et al., 2006). PDGF-
BB plays an important role in regulating a variety of glioma
cell functions, including motility, survival and proliferation
(Shih and Holland, 2006). PDGF-BB stimulates cell migration,
through the recruitment of adaptor proteins, protein kinases,
protein phosphatases and small GTPases into large multi-
protein complexes required for the regulation of cell motility
(Takahashi et al., 2008). Although these complexes have been
described, it is not yet fully understood how these signalling
molecules are coordinated to produce chemotactic responses to
PDGF.
Downstream of kinase 1 (DOK1) is a 62-kDa protein that is
phosphorylated by both receptor and non-receptor tyrosine kinases
(Carpino et al., 1997; Yamanashi and Baltimore, 1997). DOK1 has
a modular domain structure, with an N-terminal pleckstrin
homology (PH) domain, followed by a phosphotyrosine-binding
(PTB) domain and containing multiple tyrosine residues in the C-
terminal region (Mashima et al., 2009). It has been proposed that
DOK1 has a role as a scaffold or adaptor protein in the formation of
multi-molecular complexes, spatially and/or temporally regulating
other signalling molecules to produce coordinated cellular
responses (Mashima et al., 2009).
Previously, we reported that tyrosine phosphorylation of
p130Cas (also known as BCAR1) plays a key role in the
PDGF-BB-induced migration of U87 glioma cells and vascular
smooth muscle cells (Evans et al., 2011; Pellet-Many et al.,
2011). Here, we investigated the role of DOK1 in PDGF-BB-
mediated cell motility and chemotactic p130Cas signalling in
malignant glioma cells. We found that PDGF-BB stimulates
DOK1 phosphorylation on Tyr 362 and 398, and that
phosphorylation at these residues is crucial for PDGF-BB-
stimulated tyrosine phosphorylation of p130Cas. Furthermore,
DOK1 mediates PDGF-BB-induced activation of the small
GTPase Rap1 (also known as TERF2IP), through a pathway
dependent on p130Cas tyrosine phosphorylation, and PDGF-BB
stimulation of glioma cell migration and 3D radial invasion are
dependent on DOK1 and Rap1. Taken together with the
expression of DOK1 in tumour biopsies from high-grade
gliomas, these results indicate that DOK1 plays a crucial role
in regulating a p130Cas–Rap1 pathway in PDGF-BB-mediated
glioma cell motility, with implications for the mechanisms
underlying the pathogenesis of human glioblastoma.
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RESULTS
DOK1 has been reported to play both positive and negative roles in
tumour progression (Berger et al., 2010; Hosooka et al., 2001;
Mercier et al., 2011), yet very little is known about DOK1 protein
expression in human tumours. We examined multiple human
glioma cell lines for their responsiveness to PDGF-BB stimulation
and DOK1 expression (Fig. 1A). DOK1 mRNA expression in
cancer was examined by searching the continuously updated
Oncomine database, based on analysis of cancer versus normal,
cancer versus cancer and Cancer Outlier Profile Analysis (COPA)
(MacDonald and Ghosh, 2006). Analysis of cancer versus normal
showed that DOK1 mRNA was moderately overexpressed in both
breast and kidney cancers, whereas it was moderately reduced in
lung cancer (supplementary material Fig. S1A). In addition to
COPA, we also investigated mRNA expression using The Cancer
Genome Atlas (TCGA) data sets that are available through
Oncomine. We found significant increases in DOK1 mRNA
expression in lung, breast and brain cancers (supplementary
material Fig. S1B). Additionally, we explored the Human Protein
Atlas for DOK1 expression in glioma. We found that DOK1 is
expressed in the majority of glioma samples and importantly
is not detected in normal brain (http://www.proteinatlas.org/
ENSG00000115325/cancer). Considering these results, we
decided to look at DOK1 protein levels in biopsies from human
gliomas. We found that the expression of DOK1 protein was
elevated in glioblastoma multiforme (GBM) biopsies (ranging
from grades 2–4) compared with normal brain tissue, which
showed very little expression (Fig. 1B).
Having established that DOK1 is expressed in several human
glioma tumour cell lines and in human glioma biopsies, we
decided to investigate the role of DOK1 in PDGF-BB-stimulated
glioma cell invasion. PDGF-BB treatment of U87MG cells
stimulated a marked increase in the phosphorylation of DOK1 at
Tyr 362 and 398. This increase was transient, peaking between 5
and 15 min post-treatment, and it declined to basal levels
after 60 min (Fig. 2A). The timecourse of DOK1 tyrosine
phosphorylation was very similar to that of PDGF-BB-induced
tyrosine phosphorylation of p130Cas, an adapter protein that
plays a key role in the migration of U87MG cells in response to
PDGF-BB (Evans et al., 2011). Because the PDGF receptor a
(PDGFRa) has been shown to be upregulated in gliomas
(Martinho et al., 2009), we investigated responses to PDGF-
AA-mediated activation of PDGFRa signalling in U87MG cells.
Although PDGF-BB stimulation caused a robust increase in
Fig. 1. DOK1 expression in human glioma cell lines and human malignant glioma biopsies. (A) DOK1 is expressed in multiple human glioma cell lines.
Levels of total and phospho-PDGFRB and total and phospho-ERK with (+) or without (2) a 5-min treatment with 50 ng/ml PDGF-BB are also shown. (B) Protein
lysates of several biopsies of human GBM (stages 2, 3 and 4, all provided with separate code numbers) separated by gel electrophoresis and probed using
antibodies against DOK1 and b-actin. Blots shown here and in all subsequent figures are representative of at least three separate experiments.
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Fig. 2. See next page for legend.
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PDGFRb tyrosine phosphorylation (Fig. 1A), no increase in
PDGFRa tyrosine phosphorylation was detectable in response to
either PDGF-AA or PDGF-BB (supplementary material Fig.
S2A). Furthermore, although PDGF-BB increased p130Cas
tyrosine phosphorylation and ERK activation in U87MG cells,
PDGF-AA had no effect on these signalling events in these cells.
By contrast, PDGF-AA treatment of human coronary artery
smooth muscle cells increased tyrosine phosphorylation of
PDGFRa, as we reported previously (Pellet-Many et al., 2011)
(supplementary material Fig. S2B).
We next looked at the role of SRC family tyrosine kinases
(SFKs), which are known to become activated in response to
PDGF-BB stimulation. Treatment with the SFK inhibitor SU6656
resulted in the inhibition of PDGF-BB-stimulated DOK1
phosphorylation on Tyr 362 and 398 (Fig. 2B), residues within
the SRC substrate consensus sequence, YXXP. SU6656 also
strongly inhibited p130Cas tyrosine phosphorylation (Fig. 2B).
To confirm the specificity of the SRC inhibitor and signalling
through PDGFR, we treated cells with an additional selective
SFK inhibitor, PP2, and the selective PDGFR inhibitor AG 1296.
Pre-treatment of U87MG cells with PP2 or AG 1296 significantly
reduced PDGF-BB-stimulated tyrosine phosphorylation of both
DOK1 and p130Cas (Fig. 2C). By contrast, treatment of the
U87MG cells with the potent FAK family inhibitor, PF573228, at
concentrations that specifically block the activity of FAK kinase
and PYK2 (also known as PTK2B) (Slack-Davis et al., 2007), had
no effect on PDGF-BB-stimulated tyrosine phosphorylation of
DOK1 and p130Cas (Fig. 2B). Phosphatidylinositide 3-kinase
(PI3K) activity has been reported to be required for DOK1
tyrosine phosphorylation in haematopoietic cells and for DOK1
membrane localisation in fibroblasts (van Dijk et al., 2000; Zhao
et al., 2001). Treatment of U87MG cells with the PI3K inhibitor
LY294002 strongly reduced PDGF-stimulated DOK1
phosphorylation at Tyr 362 and Tyr 398, and also reduced
AKT activity compared with the vehicle control (Fig. 3A).
Furthermore, immunofluorescence microscopy indicated that
LY294002 treatment reduced the amount of DOK1 that was
localised at the cell membrane in U87MG cells following PDGF-
BB treatment (Fig. 3B).
The results in Fig. 2 suggested that DOK1 could be an
important endogenous mediator of p130Cas signalling in the
regulation of cell motility. This was examined by testing the
effect of DOK1 silencing on PDGF-BB-stimulated p130Cas
tyrosine phosphorylation. Treatment of U87MG cells with
PDGF-BB strongly increased the level of p130Cas tyrosine
phosphorylation after 5 min, an effect that was markedly reduced
when cells were treated with multiple siRNAs directed against
DOK1 (Fig. 4A). These results were further supported by the
finding that PDGF-BB-induced tyrosine phosphorylation of
p130Cas was similarly inhibited by multiple DOK1 siRNAs in
the glioma cell line U251MG (supplementary material Fig. S3A).
Inhibition of p130Cas tyrosine phosphorylation by DOK1
knockdown was selective, because PDGF-BB-mediated
phosphorylation of ERK and AKT, two signalling molecules
with well-established roles in regulating cell migration, were
unaffected by treatment with DOK1 siRNA (Fig. 4B). We also
examined the effect of PDGF-BB treatment on the localisation
of DOK1 and p130Cas in U87MG cells, by performing co-
immunofluorescent staining. PDGF-BB increased the localisation
of DOK1 and p130Cas to the cell membrane, accompanied by a
significant increase in the colocalisation of these proteins
(Fig. 5), which was blocked by pre-treatment with the selective
PDGFR inhibitor AG 1296 (supplementary material Fig. S2C),
indicating that PDGF-BB has a similar effect on cellular
redistribution of DOK1 and p130Cas.
We next investigated a possible role for DOK1 and p130Cas in
regulating Rap1 activity in glioma cells. PDGF-BB treatment of
U87MG cells strongly increased Rap1–GTP levels, as determined
by pulldown of active GTP-bound Rap1. This effect was
significantly reduced in cells that were either transfected with
DOK1 siRNAs (Fig. 6A) or that overexpressed the non-
phosphorylatable p130Cas15F mutant (Fig. 6B) (Evans et al.,
2011) compared with controls. Because the Rac1 GTPase has also
been shown to become activated downstream of p130Cas, we
investigated a possible role for DOK1 in Rac1 activation. PDGF-
BB treatment of U87MG cells modestly increased Rac1–GTP
levels, as determined by pulldown of active GTP-bound Rac1, but
this effect was not reduced in cells that were transfected with
DOK1 siRNA (data not shown).
These results led us to examine whether DOK1 tyrosine
phosphorylation at Tyr 362 and 398 was important for mediating
PDGF-BB signalling through p130Cas and Rap1. To do this, we
infected U87MG cells with adenoviruses encoding either wild-
type DOK1 (Ad.DOK1) or DOK1 with Tyr 362 and 398 mutated
to phenylalanine (Ad.DOK1FF). As shown in Fig. 6C, expression
of Ad.DOK1FF significantly decreased PDGF-BB-stimulated
p130Cas tyrosine phosphorylation, whereas expression of
Ad.DOK1 had no effect. Ad.DOK1FF expression also resulted
in a significant decrease in Rap1 activation in response to PDGF-
BB, whereas Ad.DOK1 had no effect on Rap1–GTP levels
(Fig. 6D).
The role of DOK1 in PDGF-BB-mediated chemotactic
migration was assessed using a transwell migration assay. In
both U87MG and U251MG glioma cells, knockdown of either
DOK1 or Rap1 significantly inhibited the ability of these cells to
migrate towards PDGF-BB (Fig. 7A,B; supplementary material
Fig. S3B). We further investigated the role of DOK1 in PDGF-
BB-stimulated motility using a 3D spheroid assay. We generated
Fig. 2. Timecourse of PDGF-BB-stimulated DOK1 and p130Cas tyrosine
phosphorylation and the requirement for SRC family kinases.
(A) U87MG cells (,80% confluent) were incubated in SFM for ,18 h prior to
treatment with either SFM plus vehicle control (2) or SFM plus 50 ng/ml
PDGF-BB (+) for the indicated times (min). Cell lysates were prepared and
immunoblotted as indicated. (B) U87MG cells (,80% confluent) were
incubated in SFM for,18 h prior to pre-incubation for 30 min with PF573228
(PF228) at 0.1 mM or 5 mM, SU6656 at 2 mM or the vehicle control (0.05%
DMSO, ‘C’), followed by treatment with SFM control (2) or 50 ng/ml PDGF-
BB (+) for 5 min. Cell lysates were then prepared, blotted and probed with
the indicated antibodies. Representative blots of at least three separate
experiments are shown in the left-hand panel. Quantification of tyrosine
phosphorylation was performed by densitometry using ImageJ, as shown in
the right-hand panel. Data from at least three independent experiments are
presented as phosphorylation relative units (RU), and show the
mean6s.e.m. Data are normalised to either total p130Cas (top panel) or
DOK1 (middle and lower panels). *P,0.01 (compared with PDGF-BB-
stimulated control, ‘C’); #P,0.05 (compared with SFM control, 2).
(C) U87MG cells (,80% confluent) were incubated in SFM for ,18 h prior to
pre-incubation for 30 min with either the Src family kinase inhibitor PP2
(10 mM), the PDGFR inhibitor AG 1296 (10 mM) or the vehicle (0.05%
DMSO, ‘C’), followed by treatment with SFM control (2) or 50 ng/ml PDGF-
BB (+) for 5 min. Cell lysates were then prepared, blotted and probed with
the indicated antibodies. Representative blots of at least three separate
experiments are shown (left-hand panel). Quantification of tyrosine
phosphorylation was performed as in B (right-hand panel). $P,0.01
(compared with PDGF-stimulated control, ‘C’); *P,0.05 (compared with SFM
control, 2).
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U87MG spheroids and embedded them in collagen I plugs
supplemented and overlaid with either serum-free medium (SFM)
or SFM containing PDGF-BB. PDGF-BB treatment for 48 h
resulted in enhanced radial invasion compared with the control
spheroids incubated in SFM, and the effect of PDGF-BB was
significantly reduced in spheroids generated from cells treated
with DOK1 siRNAs (Fig. 7C). We next examined the role of
DOK1 phosphorylation in PDGF-BB-mediated radial invasion.
Ad.DOK1FF expression in U87MG cells significantly inhibited
invasion induced by PDGF-BB, whereas Ad.DOK1 had no
significant effect on radial invasion compared with the Ad.LACZ
control (Fig. 7D). We also investigated the contribution of each
of the tyrosine residues (Tyr 362 and Tyr 398) on PDGF-BB-
stimulated DOK1 signalling by infecting cells with adenoviruses
expressing the single DOK1 point mutations Y362F and Y398F.
Expression of either DOK1 Y362F or DOK1 Y398F in U87MG
cells caused a significant decrease in PDGF-BB-stimulated
p130Cas tyrosine phosphorylation and 3D radial invasion
(supplementary material Fig. S4; Fig. 7D). The role of Rap1 in
radial invasion was addressed by silencing Rap1 expression using
targeted siRNAs. Three different Rap1-specific siRNAs all
significantly reduced the stimulation of radial U87MG spheroid
cell invasion in collagen I (Fig. 7E).
DISCUSSION
The role of DOK1 in tumorigenesis is still emerging and remains
unclear. Some studies suggest a role for DOK1 as a tumour
suppressor or negative regulator of tumour progression (Berger
et al., 2010; Mercier et al., 2011). By contrast, there are reports
that DOK1 plays a positive role in tumour progression and
motility (Hosooka et al., 2001; Mercier et al., 2011). Indeed, in a
gene expression profiling study of invasive carcinoma cells
versus primary mammary tumours, DOK1 was found to be
significantly upregulated in the invasive cell population (Wang
et al., 2004). We used COPA, an algorithm developed to identify
an oncogene expression profile where high gene expression is
seen in a subset of samples in the total population within a cancer
type (MacDonald and Ghosh, 2006), to analyse DOK1 expression
in various human cancers. The value of this analysis is
highlighted by the ERBB2 oncogene, which is overexpressed in
25% of breast cancers. Standard analysis does not indicate
significant ERBB2 mRNA upregulation, whereas COPA reveals a
strong and significant upregulation of ERBB2. Using COPA, we
found reduced levels of DOK1 in several cancers, particularly
leukaemia, but COPA also revealed that overexpression of DOK1
is strongly associated with brain, kidney and liver cancer and
lymphoma. In addition, we used Oncomine to search TCGA,
which contains high-resolution genetic information on several
types of cancers. Data sets are presented for individual cancer
types as well as comparisons with corresponding normal (non-
cancerous) tissue samples. We found significant increases in
DOK1 mRNA expression in several cancers, including GBM
versus normal brain. Although increased mRNA expression
suggests a role for DOK1 in specific cancers, there are limitations
in correlating this to protein expression and function. We
therefore investigated DOK1 protein expression in cancer using
the Human Protein Atlas. In agreement with DOK1 mRNA
expression, we found that DOK1 protein is expressed in the
Fig. 3. PI3K is required for DOK1 phosphorylation and recruitment to the membrane. (A) U87MG cells (,80% confluent) were incubated in SFM for,18 h
prior to pre-incubation for 30 min with LY294002 (10 mM) or the vehicle (0.05% DMSO, ‘C’), followed by treatment with SFM vehicle control (2) or 50 ng/ml
PDGF-BB (+) for 5 min. Cell lysates were then prepared, blotted and probed with the indicated antibodies. (B) U87MG cells were seeded onto glass coverslips
and incubated in SFM for ,18 h prior to pre-incubation for 30 min with LY294002 (10 mM) or the vehicle (0.05% DMSO), followed by treatment with SFM vehicle
control (2) or 50 ng/ml PDGF-BB (+) for 5 min. Confocal imaging was performed as described in Materials and Methods, with DOK1 staining shown in green.
Images are representative of at least three separate experiments. Arrows indicate areas of increased DOK1 localisation to the membrane upon PDGF-BB
treatment.
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majority of the available glioma samples and is not detected in
normal brain. Furthermore, our results showed higher DOK1
protein expression in several grade 2, 3 and 4 glioma biopsies
compared with normal brain tissue, in which DOK1 protein
expression was undetectable.
Although DOK1 has been implicated in the regulation of
epithelial and smooth muscle cell motility (Lee et al., 2004; Ling
et al., 2005), the mechanisms involved in regulating DOK1 and
its downstream signalling pathways in tumour cell motility are
not well understood. In this study, PDGF-BB stimulation resulted
in a transient increase in DOK1 tyrosine phosphorylation,
indicating that DOK1 phosphorylation is regulated by the
PDGF-BB signalling pathway. The exact mechanism of DOK1
tyrosine phosphorylation is unclear, with reports of both SFK-
dependent and SFK-independent mechanisms (Liang et al., 2002;
Senis et al., 2009). Our data demonstrate that, in glioma cells,
PDGF-BB-induced DOK1 tyrosine phosphorylation is dependent
on SFK. Furthermore, treatment with a PI3K inhibitor strongly
decreased PDGF-BB-stimulated DOK1 tyrosine phosphorylation
and also reduced DOK1 localisation at the cell membrane,
consistent with previous findings in other cell types (van Dijk
et al., 2000; Zhao et al., 2001). This suggests that PI3K is
required for DOK1 recruitment to the cell membrane, and such
recruitment might be needed for its phosphorylation by SFK.
We recently reported that tyrosine phosphorylation of the
adaptor protein p130Cas plays a key role in PDGF-BB-dependent
migration of glioma cells and vascular smooth muscle cells
(Evans et al., 2011; Pellet-Many et al., 2011). DOK1 has been
reported to associate with p130Cas upon stimulation of type 1 Fce
receptors (FceRI) in mast cells, but the nature of this association
is unclear, and the effect on p130Cas tyrosine phosphorylation
was not determined (Abramson et al., 2003). Indeed, we
attempted to co-immunoprecipitate p130Cas with endogenous
and tagged DOK1, but were unable to observe any association
between DOK1 and p130Cas, in contrast to the results
reported by Abramson et al. Nevertheless, we show herein that
DOK1 is required for PDGF-BB-induced p130Cas tyrosine
phosphorylation and that both DOK1 and p130Cas colocalise
to the membrane following stimulation with PDGF-BB.
Furthermore, DOK1 has a selective role in regulating PDGF-
BB-stimulated tyrosine phosphorylation of p130Cas, because
DOK1 knockdown did not significantly affect other major
receptor tyrosine kinase (RTK) signal transduction pathways,
including activation of the ERK and AKT signalling pathways.
Through its multiple domains, p130Cas is thought to function
as a scaffold for the assembly of signalling complexes that are
required for remodelling of the cytoskeleton during cell motility
(Barrett et al., 2013; Defilippi et al., 2006). A key role of p130Cas
is in the formation of complexes with exchange factors for Ras
family small GTPases (Di Stefano et al., 2011). In particular,
p130Cas, through its N-terminal SH3 domain, binds to the
adaptor protein Crk, and both p130Cas and Crk associate with the
guanine nucleotide exchange factor (GEF) C3G (also known as
RAPGEF1). This results in the recruitment of the small GTPase
Rap1, and its activation through exchange of GDP for GTP. In
turn, Rap1 activation drives multiple signalling pathways that are
Fig. 4. DOK1 specifically regulates PDGF-BB-stimulated tyrosine phosphorylation of p130Cas. (A) U87MG cells were transfected with three independent
siRNAs targeting DOK1 (siDOK1, 25 nM) or with control scrambled siRNA (siScr, 25 nM). At 48 h post-transfection, cells were incubated in SFM for ,18 h prior
to treatment with SFM containing vehicle control (2) or 50 ng/ml PDGF-BB (+) for 5 minutes. Cell lysates were then prepared, blotted and probed with the
indicated antibodies. Quantification of p130Cas phosphorylation was performed by densitometry using ImageJ. Data from three independent experiments are
presented as p130Cas phosphorylation relative units (RU) and shown as the mean6s.e.m. Data are normalised to total p130Cas. *P,0.05; **P,0.01
(compared with ligand-stimulated siScr). (B) U87MG cells were treated as above and probed with the indicated antibodies.
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required for RTK-mediated cell motility (Boettner and Van
Aelst, 2009; Frische and Zwartkruis, 2010). Our finding that
either DOK1 knockdown or overexpression of Ad.DOK1FF
inhibits p130Cas tyrosine phosphorylation and Rap1 activation
supports the conclusion that PDGF-BB-induced DOK1 tyrosine
phosphorylation plays a key role in mediating a signalling
pathway involving p130Cas and Rap1.
Consistent with its role in Rap1 activation, assays of
chemotaxis and 3D invasion showed that DOK1 is required for
PDGF-BB-stimulated cell motility. Examination of chemotactic
tumour cell invasion in a 3D environment has proven to be
difficult, owing to the difficulties in establishing a defined
chemotactic gradient. We sought to overcome this problem by
using the spheroid invasion model with exogenously supplied
PDGF-BB. Although this is not a model of movement towards a
single chemotactic source, it does produce directional radial
movement outwards from the rim of the spheroid core. DOK1
knockdown or expression of Ad.DOK1FF inhibited spheroid
outgrowth, as did Rap1 silencing. These results further establish
an important role for DOK1 in regulating PDGF-BB-mediated
signalling, which is essential for cell motility and invasion.
Taken together, these results show for the first time that DOK1
and p130Cas play an important role in the regulation of PDGF-
BB-stimulated Rap1 signalling in U87MG glioma cells. The
finding that Tyr 362 and 398 are crucial for PDGF-BB-stimulated
p130Cas tyrosine phosphorylation and Rap1 activation suggests
an important role for the signalling protein(s) that bind either one
or both of these residues. Furthermore, these data show that the
Ad.DOK1FF mutant behaves in a dominant-negative manner,
possibly by competing with endogenous DOK1 binding partners
to form non-functional complexes. The adaptor proteins Crk
and NCK have been reported to bind to DOK1 and to p130Cas
(Defilippi et al., 2006; Noguchi et al., 1999). However,
knockdown (,80%) of either Crk or NCK with targeted
siRNAs had no significant effect on PDGF-BB-stimulated
tyrosine phosphorylation of p130Cas or DOK1, suggesting that
they might act further downstream (data not shown).
It is likely that DOK1 associates with other as-yet-unidentified
binding partner(s). DOK1 was originally described as a binding
protein and substrate for the Abl tyrosine kinase (Yamanashi and
Baltimore, 1997), and an Abl pathway has been implicated in
regulating cell motility (Woodring et al., 2004). We therefore
investigated the role of Abl using siRNA-mediated knockdown.
However, we were unable to demonstrate a significant effect of
silencing Abl on PDGF-BB-mediated stimulation of DOK1 and
p130Cas tyrosine phosphorylation (data not shown). This
suggests that Abl might not be important for DOK1-mediated
PDGF-BB signalling through the p130Cas pathway described
here. However, these results do not preclude a role for Abl in
DOK1-dependent signalling in glioma cells, and this warrants
further investigation. We found that expression of the single
mutants DOK1 Y362F and, to a lesser extent, DOK1 Y398F
Fig. 5. PDGF-BB-mediated increase in
colocalisation of DOK1 and
phosphorylated p130Cas. U87MG cells
were seeded onto glass coverslips and
incubated in SFM for ,18 h prior to
treatment with SFM control (serum free) or
50 ng/ml PDGF-BB for 5 min. Confocal
imaging was performed as described in
Materials and Methods, with DOK1
staining shown in green and phospho-
p130Cas (Y410) shown in red (upper
panel). Merged images show co-staining
of DOK1 and phospho p130Cas (yellow)
and are representative of at least three
separate experiments. Arrows indicate
membrane regions and areas of increased
colocalisation upon PDGF-BB treatment.
Quantification of DOK1 and phospho-
p130Cas colocalisation (as described in
Materials and Methods) is shown (lower
panel) and represents data from three
independent experiments expressed as
Pearson’s coefficient of colocalisation.
Data show the mean6s.e.m. *P,0.05,
compared with SFM control (two-tailed
Student’s t-test).
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Fig. 6. DOK1 and p130Cas are required for Rap1 activation. (A) U87MG cells were transfected with three independent siRNAs targeting DOK1
(siDOK1, 25 nM) or with control scrambled siRNA (siScr, 25 nM). At 48 h post-transfection, cells were incubated in SFM for ,18 h prior to treatment with SFM
containing vehicle control (2) or 50 ng/ml PDGF-BB (+) for 5 min. Cell lysates were prepared and assayed using a Rap1 activation assay, as described in
Materials and Methods. Rap1–GTP and whole-cell extract samples were blotted and probed with the indicated antibodies. Quantification of Rap1–GTP levels
was performed by densitometry using ImageJ. Data from three independent experiments are presented as Rap1–GTP relative units (RU) and show the
mean6s.e.m. Data are normalised to total Rap1. **P,0.01 (compared with ligand-stimulated siScr). (B) U87MG cells (,80% confluent) were infected with
Ad.LacZ, Ad.p130Cas or Ad.p130Cas15F at MOIs of 250. At 48 h after infection, cells were treated as described above and quantification of Rap1–GTP levels
was performed as for A. *P,0.05 (compared with ligand-stimulated Ad.LacZ); §P,0.05 (compared with Ad.LacZ SFM control). (C) U87MG cells (,80%
confluent) were infected with Ad.LacZ, Ad.DOK1 or Ad.DOK1FF at MOIs of 200. At 48 h after infection, cells were incubated in SFM for ,18 h prior to treatment
with SFM control (2) or 50 ng/ml PDGF-BB (+). Cell lysates were then prepared, blotted and probed with the indicated antibodies, and p130Cas
phosphorylation was quantified. **P,0.01 (compared with Ad.LacZ plus PDGF-BB). (D) U87MG cells were treated as in C, lysed in Rap1 activation buffer and
analysed using a Rap1 activation assay as described in Materials and Methods. Quantification of Rap1–GTP levels was performed as for A; *P,0.05 compared
with Ad.LacZ plus PDGF-BB.
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Fig. 7. DOK1 and Rap1 are required for PDGF-BB-
stimulated chemotactic motility and 3D radial invasion
of U87MG spheroids. (A) U87MG cells were transfected
with three independent siRNAs targeting DOK1 (siDOK1,
25 nM) or with control scrambled siRNA (siScr, 25 nM). At
48 h post-transfection, cells were used in a transwell
migration assay as detailed in Materials and Methods.
Data are representative of three separate experiments and
show the mean6s.e.m., expressed as the number of cells
migrating per field. *P,0.01 (compared with siScr);
$P,0.05 (compared with siScr SFM control). (B) U87MG
cells were transfected with three independent siRNAs
targeting Rap1 (siRap1, 25 nM) or with control scrambled
siRNA (25 nM). At 48 h post-transfection, cells were used
in a transwell migration assay as detailed in Materials and
Methods. Data are presented as for A. *P,0.01
(compared with siScr); $P,0.05 (compared with siScr
SFM control). (C) U87MG cells were transfected with three
independent siRNAs targeting DOK1 (25 nM) or with
control scrambled siRNA (25 nM). **P,0.01 (compared
with siScr plus PDGF-BB). (D) U87MG cells (,80%
confluent) were infected with Ad.LacZ, Ad.DOK1,
Ad.DOK1FF, Ad.DOK1 Y362F or Ad.DOK1 Y398F at
MOIs of 200. **P,0.01 compared with Ad.LacZ plus
PDGF-BB. (E) U87MG cells were transfected with three
independent siRNAs targeting Rap1 (25 nM) or with
control scrambled siRNA (25 nM). Representative levels
of Rap1 and GAPDH expression are shown (left-hand
panel). **P,0.01 (compared with siScr plus PDGF-BB).
(C–E) At 24 h post infection or transfection, cells were re-
suspended and equal amounts of cells were used to
generate spheroids as described in Materials and
Methods. At 24 h after spheroid production, spheroids
were imbedded in a collagen gel and incubated in SFM
containing vehicle control (2) or 50 ng/ml PDGF-BB (+)
for an additional 48 h. Spheroids were fixed in 4%
paraformaldehyde and invasion was determined by
measuring the area corresponding to the invasion rim (red
dashed line) minus the area of the core for at least four
different spheroids per condition. Data from at least three
independent experiments are presented as relative area
units (RU) and show the mean6s.e.m.
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significantly decreased PDGF-BB-stimulated p130Cas tyrosine
phosphorylation and 3D radial invasion, indicating that
phosphorylation of either Tyr 362 or Tyr 398 is required for
DOK1 function in PDGF-BB signalling. This is likely due to the
requirement of specific DOK1-binding proteins to form a multi-
protein signalling complex required for Rap1 activation and cell
motility. Understanding the precise role of these important
tyrosine residues will be the basis of future investigations.
This is the first study clearly establishing a role for DOK1
in the positive regulation of tumour cell motility. Our findings
that DOK1 regulates PDGF-BB-mediated glioma cell motility
through a novel signalling pathway involving p130Cas and Rap1
significantly advance our understanding of DOK1 signalling and
function.
MATERIALS AND METHODS
Cell culture
U87 and U251 glioma cells were cultured in DMEM containing 10%
fetal calf serum (FCS) supplemented with penicillin-streptomycin (1:100;
P4333, Sigma).
Derivation of surgical biopsies
All patients gave informed consent before the surgical intervention. The
storage of human tissue is governed by the Human Tissue Act (UK; HTA
Licence numbers 12054 and 12198). The use of tissue and cells was
approved by the National Hospital Ethics Committee (LREC 08/0077 and
02/N093). Neurosurgical biopsies were obtained at the operating theatre or
in post-mortem and immediately transferred into the Department of
Neuropathology, where they were dissected for tissue processing. Samples
were homogenised in RIPA buffer with protease and phosphatase
inhibitors (Roche) using sonication. The homogenates were then spun at
10,000 g for 10 min, and the protein concentration of the resulting
supernatant was measured using the Bio-Rad protein assay kit.
Antibodies, reagents and siRNA
Antibodies against PYK2, phospho-PYK2 (Y402), phospho-p130Cas
(Y410), ERK, phospho-ERK (T202/Y204), phospho-Src (Y416) and
phospho-PDGFR-b (Y751) were from Cell Signaling Technology
(Danvers, MA). Antibodies against phospho-DOK1 (Y398), DOK1 N-
terminus (E-16), phospho-PDGFR-a (Y754), PDGFR-a (C-20), PDGFR-b,
FAK (A-17), Rap1, GAPDH (V-18) and tubulin (TU-02) were from Santa
Cruz Biotechnology (Heidelberg, Germany). Secondary antibodies against
mouse, goat and rabbit IgGs were also from Santa Cruz Biotechnology.
Antibody against the DOK1 C-terminus was from Abcam (Cambridge, UK),
antibody against total DOK1 was from Abnova (Taipei City, Taiwan) and
anti-p130Cas monoclonal antibody was from BD Transduction Laboratories
(Oxford, UK). Antibody against phospho-DOK1 (Y362) was from ECM
Biosciences (Versailles, KY) and antibody against phospho-FAK (Y397)
was from Invitrogen (Paisley, UK). Alexa-Fluor-486-conjugated donkey
anti-goat-IgG, Alexa-Fluor-546-conjugated donkey anti-rabbit-IgG and
Alexa-Fluor-555–phalloidin were from Invitrogen (Paisley, UK). The Src
inhibitor SU6656, the Src/Abl inhibitor 1-naphthyl PP1 and the Fak/Pyk2
inhibitor PF573228 were all purchased from Tocris Bioscience (Bristol,
UK). PDGF-BB was purchased from Peprotech (London, UK).
The following siRNAs were purchased from Applied Biosystems
(Warrington, UK): siDOK1-1, 59-GGGCCTTTATGATCTGCCT-39;
siDOK1-2, 59-GGATGCATGGTGGTGCCAA-39. The following siRNAs
were purchased from Qiagen (Crawley, UK): AllStars negative control;
siDOK1-3, 59-CCGCCTGGACTGCAAAGTGAT-39; siRap1A-1, 59-
AAAGTCAAAGATCAATGTTAA-39; siRap1A-2, 59-AAGTCGATTGC-
CAACAGTGTA-39; siRap1A-3, 59-CCCAACGATAGAAGATTCCTA-39.
siRNA transfection
U87 and U251 glioma cells at 60% confluence were transfected by using
Lipofectamine 2000 (Invitrogen), with a final siRNA concentration of
25 nM.
Adenoviral construction and infection
Adenoviruses expressing wild-type DOK1, DOK1FF (Y362F, Y398F),
DOK1 Y362F and DOK1 Y398F were generated using the GATEWAYTM
vector (pAd/CMV/V5-DEST; Invitrogen) and were verified by DNA
sequencing. Prior to cloning into the pENTR3C vector, the indicated
mutations in DOK1FF were generated using the QuikChange Multi-
Site-Directed Mutagenesis Kit (Agilent Technologies, Cheshire, UK).
The following primers were used for multi-site-directed mutagenesis,
designed and used according to the manufacturer’s instructions:
Y362F, 59-CCCAAAGAGGATCCCATCTTTGATGAACCTGAGGGC-
CTG-39; Y398F, 59-CGGGTGAAGGAGGAGGGCTTTGAGCTCCCC-
TACAACCCT-39. DOK1 adenoviral expression vectors (pAd/CMV/
V5-DEST; Invitrogen) were generated by recombination, and
adenovirus was produced by transfection into host HEK293A cells
(Invitrogen). Viral particles were purified by caesium chloride
centrifugation, and the virus titre was determined by immunoassay
(QuickTiter Adenovirus Titer Immunoassay kit; Cell Biolabs, San
Diego, CA). Adenovirus was stored at 220 C˚. U87MG cells were
infected with adenovirus expressing either LacZ (Ad.LacZ), DOK1
(Ad.DOK1) or DOK1FF (Ad.DOK1FF) at a multiplicity of infection
(MOI) of 200.
Immunoblotting
For immunoblotting, cells were lysed in a solution containing 50 mM Tris-
HCl pH 7.5, 1% Triton X-100, 150 mM NaCl, 5 mM EDTA, complete
protease inhibitor (Roche) and phosphatase inhibitors I and II (Sigma), and
the resulting cell lysates were analysed by SDS-PAGE on 4–12% Bis-Tris
gels (Nupage, Invitrogen), followed by electrotransfer onto polyvinylidene
fluoride (PVDF) membranes (Invitrogen). Membranes were blocked with
5% (w/v) non-fat dry milk and 0.1% (v/v) Tween-20 in phosphate-buffered
saline (PBS-T) for 1 h at room temperature, before being probed with the
primary antibody by overnight incubation at 4 C˚, followed by incubation
for 1 h at room temperature with a horseradish peroxidase (HRP)-linked
secondary antibody (Santa-Cruz Biotechnolgy) and detection using
ECL reagents (GE Healthcare, Little Chalfont, UK), following the
manufacturer’s protocol. Immunoblots were quantified by scanning of
films with a calibration strip and analysis by densitometry using ImageJ
(National Institutes of Health).
Immunofluorescent staining and confocal imaging
For immunofluorescent staining, cells were fixed in 4%
paraformaldehyde in PBS for 60 min followed by permeabilisation in
0.2% Triton X-100 for 30 min. Antibody incubations were performed
overnight at 4 C˚ in 1% bovine serum albumin (BSA), 0.1% Tween 20 in
PBS. Confocal imaging was performed using a LEICA SPE2 upright
microscope running LEICA-LAS software using sequential imaging
capture. Co-localisation of DOK1 and phosphorylated p130Cas (Y410)
was quantified using the ImageJ plugin JACoP (Bolte and Cordelie`res,
2006). Both the DOK1 and Y410 p130Cas channels were analysed, and
the resultant Pearson’s coefficient of colocalisation was determined.
Rap1 activation assay
Rap1–GTP levels were determined using a specific activation assay.
U87MG cells were treated as indicated and harvested in activation buffer
[50 mM Tris-HCl, 10% glycerol, 1% NP-40, 5 mM MgCl2, 100 mM NaCl,
1 mM tris-(2-carboxyethyl)phosphine (TCEP), EDTA-free complete
protease inhibitor and phosphatase inhibitors]. The GST–Rap1 binding
domain of RalGDS was coupled to glutathione–Sepharose beads (GE
Healthcare Life Sciences, Buckinghamshire, UK). Lysates were incubated
with the bead-bound probe to precipitate GTP-bound Rap1. Rap1–GTP was
released from the beads upon the addition of 26 SDS buffer. Western
blotting was carried out on pulldown samples and normalised to total Rap1
levels as determined by western blot analysis of the whole-cell lysate.
Transwell chemotactic migration assay
This assay was performed as described previously (Evans et al., 2011).
Briefly, transwell cell culture inserts (Falcon; BD Biosciences, Oxford,
UK) were inserted into a 24-well plate. Serum-free medium
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supplemented with or without PDGF-BB or vehicle was added to the
bottom chamber, and U87 or U251 glioma cells in suspension (1.56105
cells/well in serum-free DMEM) were added to the top chamber and
incubated at 37 C˚ for 6 h. Cells that had not migrated or had only adhered
to the upper side of the membrane were removed before membranes were
fixed and stained with a Reastain Quik-Diff kit (IBG Immucor, West
Sussex, UK). Cells that had migrated to the lower side of the membrane
were counted in four random fields per well at 206magnification using
an eyepiece indexed graticule.
3D spheroid invasion assay
Spheroids were generated using the metho-cellulose technique as
described previously (Augustin, 2004). Virus infection and siRNA
transfection were carried out on U87 cells as described previously
(Evans et al., 2011). Following the infection and transfection period, cells
were trypsinised and 36105 cells/ml were suspended in a 4:1 (v/v) mixture
of 10% FCS in DMEM and methylcellulose. Spheroids were produced by
pipetting 100 ml of the cell suspension into a well of a 96-well round-
bottomed non-tissue-culture plate and incubating for 24 h (37 C˚, 5% CO2).
Spheroids were collected and embedded in collagen I plugs (2.1 mg/ml)
prepared from fibrillar bovine collagen I (3.1 mg/ml; PureCol) by dilution
in DMEM, in accordance with the manufacturer’s protocol (Nutacon, The
Netherlands). The collagen I solution was supplemented with either dH2O
(2) or 50 ng/ml PDGF-BB (+). Plugs were overlaid with SFM (2) or SFM
plus 50 ng/ml PDGF-BB (+). Spheroids were allowed to invade for 48 h,
followed by fixation in 4% formaldehyde. Spheroid invasion was
determined by measuring the circular area of the spheroid core and the
rim of invasion using ImageJ. The rim of invasion was determined as the
circular distance from the edge of the core to the edge of contiguous
invading cells (Stein et al., 2007).
ELISA assay for PDGFR activity
An immobilised capture antibody specific for human PDGFR recognises
both tyrosine phosphorylated and nonphosphorylated PDGFR. After
washing away unbound material, an HRP-conjugated detection antibody
specific for phosphorylated tyrosine was used to detect only the tyrosine-
phosphorylated receptor, using HRP. The capture antibody was diluted to a
working concentration of 4 mg/ml in PBS without carrier protein, and
100 ml was immediately added to a 96-well microplate for overnight
incubation at room temperature. The next day, each well was washed four
times with washing buffer (0.05% Tween 20 in PBS, pH 7.2) and blocked
for 2 h with 300 ml of PBS containing 1% BSA. Wells were washed again
three times before adding 100 ml of lysate prepared in the following
diluent: 1% Nonidet P40, 20 mM Tris-HCl pH 8.0, 137 mM NaCl, 10%
glycerol, 2 mM EDTA and 1 mM activated Na3VO4. The same diluent
without protein was used as a blank. The plate was left to incubate for 2 h
at room temperature and washed again. Then, 100 ml of detection antibody
diluted to the manufacturer’s recommendations in 20 mM Tris-HCl
pH 7.2, 137 mM NaCl, 0.05% Tween 20 and 0.1% BSA was added
directly to the well, before incubation for a further 2 h. Finally, after three
further washes, 100 ml of substrate solution was added to each well for
20 min, followed by incubation with 50 ml of stop solution (1M H2SO4).
The absorbance of each well was determined immediately, using a
microplate reader set to 450 nm with a wavelength correction of 595 nm.
Total PDGFR levels and equal loading was assessed by western blotting.
Statistical analysis
The data displayed on the graphs are means, with error bars representing
the standard error of the mean (s.e.m.). Statistical analysis was performed
by two-way analysis of variance (ANOVA) or t-test, as appropriate.
P,0.05 was considered significant.
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Supplementary Figure Legends 
Supplementary Figure S1: Oncomine Analysis: Disease Summary and TCGA analysis 
for DOK1. (A) The Oncomine database (OncomineTM, Compendia Bioscience, Ann Arbor, 
MI). was queried for DOK1 expression in the available datasets based on the following 
analysis: cancer vs normal, cancer vs. cancer, and Cancer Outlier Profile Analysis (COPA).  
Threshold values used were; Fold change=2 and p-value of 1E-4. The ‘red cells’ represents 
DOK1 overexpression and the ‘blue cells’ represent DOK1 underexpression. The levels of 
expression are based on the gene rank percentile. (B) The Oncomine database was queried for 
DOK1 mRNA expression within The Cancer Genome Atlas (TCGA) data sets indicated. 
Individual cancers or comparisons, significance, fold change and gene overexpression 
ranking are listed for each cancer.  
 
Supplementary Figure S2: PDGF-BB but not PDGF-AA mediates  p130Cas tyrosine 
phosphorylation and PDGF receptor inhibition blocks p130Cas and DOK1 co-
localisation. (A) U87MG cells were incubated overnight in serum-free medium and then 
treated for 10 min with serum-free medium (control), 30 ng/ml PDGF-AA or 30 ng/ml 
PDGF-BB. Cells were then lysed, and the activity of either PDGFRα (left) or PDGFRβ 
(right) was measured using a specific ELISA. Results are means ± S.E.M. obtained from 
three independent experiments each performed in triplicate. *P < 0.05 Serum Free versus plus 
PDGF-BB. Similarly, total PDGFRs protein levels were assessed by Western blotting and 
equal loading was checked by assessing β-actin levels. (B) HCASMCs were incubated 
overnight in serum-free medium and then treated for 10 min with serum-free medium 
(control), 30 ng/ml PDGF-AA or 30 ng/ml PDGF-BB. Cells were then lysed, and the activity 
of either PDGFRα (left) or PDGFRβ (right) was measured using a specific ELISA. Results 
are means± S.E.M. obtained from three independent experiments each performed in 
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triplicate. *P < 0.05 Serum Free versus plus PDGF- AA or PDGF-BB. Total PDGFRs protein 
levels were assessed by Western blotting (sc-338 and sc-339 for PDGFRα and PDGFRβ 
respectively, Santa Cruz biotechnology, Inc.) and equal loading was checked by assessing β-
actin levels (A5316, Sigma-Aldrich). (C) U87MG cells were seeded on glass cover slips and 
incubated in SFM for ~18h prior to treatment. Cells were then pre-treated with AG1296 at 
10M or the vehicle (DMSO) for 30 minutes prior to treatment with SFM control (SFM) or 
treated with 50 ng/ml PDGF-BB for 5 minutes. Confocal imaging was performed as 
described in Materials and Methods, with DOK1 staining in green and Y410 phospho 
p130Cas in red. Merged images show co-staining of DOK1 and Y410 phospho p130Cas in 
yellow, and are representative of at least three separate experiments. Quantification of DOK1 
and Y410 phosphop130Cas  co-localisation (as described in Materials and Methods) is shown 
in the graphs and represents data from three independent experiments expressed as Pearson's 
Coefficient of co-localisation (means +/- s.e.m). *p<0.05 compared to SFM Control by two-
tailed student’s T-test. 
 
Supplementary Figure 3: DOK1 is required in U251 cells for p130Cas tyrosine 
phosphorylation and DOK1 and Rap1 are required for PDGF-stimulated chemotactic 
motility. (A) U251MG cells were transfected with two independent siRNA targeting DOK1 
(siDOK1) at a concentration of 25 nM, or 25 nM of a control scrambled siRNA (siScr). 48hr 
post transfection, cells were incubated in serum-free medium (SFM) for ~18hr prior to 
treatment with SFM vehicle control (-) or treated with 50 ng/ml PDGF-BB (+) for 5 minutes. 
Cell lysates were then prepared, blotted, and probed with the indicated antibodies. The blots 
shown are representative of three independent experiments. (B) U251MG cells were 
transfected with two independent siRNA targeting DOK1 (siDOK1) or Rap1 (siRap1) at a 
concentration of 25 nM, or 25 nM of a control scrambled siRNA (siScr). 48hr post 
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transfection, cells were used in a Transwell migration assay as detailed in Materials and 
Methods. Values (n ≥ 3) are means ± s.e.m, expressed as the number of cells migrating per 
field; *p<0.01 compared to siScr, $ p<0.01 compared to untreated control (-). 
 
Supplementary Figure 4: Tyrosine 362 and 398 on DOK1 are required for PDGF 
stimulated tyrosine phosphorylation of p130Cas and 3D radial invasion of U87MG 
spheroids. U87MG cells (~80% confluent) were infected with Ad.LacZ, Ad.DOK1, 
Ad.DOK1FF, Ad.DOK1 (Y362F) or Ad.DOK1 (Y398F) at MOIs of 200 48 h after infection, 
cells were incubated in SFM for ~18hr prior to treatment with SFM control (-) or treated with 
50 ng/ml PDGF-BB (+). Cell lysates were then prepared, blotted, and probed with the 
indicated antibodies, and p130Cas phosphorylation was quantified.  **p<0.01 compared to 
Ad.DOK1 plus PDGF. $p<0.05 compared to SFM control (-).  
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